drugset / Trial / NCT04254471
This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients
RandomizedSequentialDouble-blindTreatment
Summary
Phase II Study is to Evaluate the Safety and tolerability of AL3810 in combination with carboplatin plus (+) etoposide in untreated participants with ES-SCLC. Phase III Study is to Evaluate the efficacy of AL3810 in combination with carboplatin plus (+) etoposide in untreated participants with ES-SCLC.
Timeline
- Start
- 2019-11-14
- Primary completion
- 2022-05-22
- Completion
- 2022-11-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lucitanib | Small molecule | 5 mg | Oral |
| Subject | Lucitanib | Small molecule | 7.5 mg | Oral |
| Subject | Lucitanib | Small molecule | 10 mg | Oral |
| Background | Carboplatin | Small molecule | — | — |
| Background | Etoposide | Small molecule | — | — |